Dual GLP-1/GIP receptor agonists (molecules engineered to simultaneously activate GLP-1R and GIPR) represent a pharmacological leap beyond classical incretin-based therapies
The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements
Octyldodecanol, Polybutene, Hydrogenated Polyisobutene, Dicalcium Phosphate, Silica, Hydrogenated Styrene/Isoprene Copolymer, Caprylic/Capric Triglyceride, Triacontanyl Pvp, Synthetic Fluorphlogopite, Pentaerythrityl Tetra-Di-T-Butyl Hydroxyhydrocinnamate, Ethyl Vanillin, Parfum (Fragrance), Dimethyl Phenethyl Acetate, Tin Oxide, CI 15850 (Red 7 Lake), CI 42090 (Blue 1 Lake), CI 77491 (Iron Oxides), CI 77492 (Iron Oxides), CI 77499 (Iron Oxides), CI 77891 (Titanium Dioxide)
Eur J Dermatol (2014) 24:594602
For example, in the STEP 1 trial , patients taking semaglutide lost an average of 14.9% of their body weight over 68 weeks , compared with just 2.4% in the placebo group (NEJM study)